Author:
Ghanbari Samin,Gohari Sepehr,Reshadmanesh Tara,Mahjani Mahsa,Arsang-Jang Shahram,Ismail-Beigi Faramarz,Dadashi Mohsen,Chiti Hossein,Asgari Atieh,Taheri Homa,Zolfkhani Ozra,Ahangar Hassan
Funder
Zanjan University of Medical Sciences
Dr Abidi Pharmaceuticals
Publisher
Springer Science and Business Media LLC
Reference21 articles.
1. Rosano GM, Vitale C, Seferovic P. Heart failure in patients with diabetes mellitus. Cardiac Fail Rev. 2017;3(1):52.
2. Novo G, Guarino T, Di Lisi D, Biagioli P, Carluccio E. Effects of SGLT2 inhibitors on cardiac structure and function. Heart Fail Rev. 2022:1–11.
3. Santos-Gallego CG, Vargas-Delgado AP, Requena-Ibanez JA, Garcia-Ropero A, Mancini D, Pinney S, et al. Randomized trial of empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction. J Am Coll Cardiol. 2021;77(3):243–55.
4. Santos-Gallego CG, Requena-Ibanez JA, San Antonio R, Garcia-Ropero A, Ishikawa K, Watanabe S, et al. Empagliflozin ameliorates diastolic dysfunction and left ventricular fibrosis/stiffness in nondiabetic heart failure: a multimodality study. Cardiovasc Imaging. 2021;14(2):393–407.
5. Hsu J-C, Wang C-Y, Su M-YM, Lin L-Y, Yang W-S. Effect of empagliflozin on cardiac function, adiposity, and diffuse fibrosis in patients with type 2 diabetes mellitus. Sci Rep. 2019;9(1):1–9.